Corcept Therapeutics ($CORT) Stock Hub 2026: Revenue Up 32% And Back To Profit, What Does The December 17 Cushing’s Decision Add?

01 Q2 delivered a genuine two-franchise beat, not merely a favorable headline

Corcept reported $256.1 million of second-quarter product revenue, up 32% year over year. Korlym and the authorized generic contributed $208.6 million, while newly launched Lifyorli contributed $47.6 million. Net income was $43.0 million, diluted EPS was $0.36, and cash plus investments increased sequentially to $544.6 million. Management raised 2026 revenue guidance from $950 million–$1.05 billion to $1.1–$1.2 billion.

The regulatory board also became clearer. The FDA accepted the resubmitted relacorilant NDA in Cushing’s syndrome and assigned a December 17, 2026 PDUFA date. The next major evidence windows are BELLA Part A and MONARCH by year-end, an expected EMA decision on relacorilant in platinum-resistant ovarian cancer in Q4, and the planned start of a pivotal dazucorilant ALS study in early 2027.

The bottom line on the quarter: the quarter materially strengthens the operating thesis because both the legacy endocrine franchise and the new oncology franchise contributed. The remaining debate is no longer whether Lifyorli can generate an initial launch signal; it is whether the launch can sustain duration, repeat prescribing and payer access while Corcept controls a permanently higher commercial cost base.

02 The numbers behind the reset

The quarter’s quality is clearest when revenue trajectory, product mix and the Q1-to-Q2 profitability bridge are viewed together. All values below come from Corcept’s reported financial statements and official releases; figures are rounded to one decimal place.

Q1-to-Q2 operating bridge

03 Corcept is now a two-product commercial company with a late-2026 regulatory binary

Corcept Therapeutics develops medicines that modulate cortisol activity through the glucocorticoid receptor. For more than a decade, the company’s commercial identity was dominated by Korlym, a mifepristone product used in a defined population of adults with endogenous Cushing’s syndrome and hyperglycemia. That product created a profitable specialty franchise and funded a broad pipeline of selective cortisol modulators.

The profile changed on March 25, 2026, when the FDA approved Lifyorli, the brand name for relacorilant, with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three prior systemic regimens, including at least one bevacizumab-containing regimen. The approval gave Corcept a second marketed product and validated its oncology thesis at the same time relacorilant’s separate Cushing’s application was recovering from a December 2025 Complete Response Letter.

Q2 is the first quarter in which investors can see the new model in reported numbers. Lifyorli’s $47.6 million contribution represented 18.6% of total product revenue despite being available for only its first quarter. More than 1,300 patients had started therapy and more than 1,000 physicians had prescribed the product to at least one patient. Management said demand accelerated each month and more than 70% of combined Medicare, Medicaid and commercial lives had formal coverage policies by the earnings call.

The endocrine side was also stronger. Korlym and authorized-generic revenue increased 7.3% year over year to $208.6 million, and management described record new prescriptions, first-time prescribers and patients receiving therapy. Crucially, it said the improvement was not primarily a temporary catch-up from the specialty-pharmacy transition: management characterized the transition as behind the company and attributed growth to existing patients plus record new enrollments.

Commercial proof

Lifyorli has passed the first uptake test, but one quarter cannot establish steady-state duration, net price or repeat-prescriber behavior.

Regulatory recovery

The Cushing’s resubmission is accepted with a December 17 PDUFA. The prior CRL still makes this a high-consequence event, not a routine extension.

Pipeline optionality

BELLA Part A and MONARCH are expected by year-end; several oncology expansion studies are expected to read out by end-2027.

04 From regulatory damage to commercial validation

05 Lifyorli changes the growth mix, but Korlym still funds the platform

Lifyorli: the launch is ahead of the initial burden of proof

Lifyorli combines an oral glucocorticoid-receptor antagonist with nab-paclitaxel chemotherapy. In ROSELLA, the combination reduced the risk of death by 35% versus nab-paclitaxel alone, with median overall survival of 16.0 months versus 11.9 months, hazard ratio 0.65 and p=0.0004. It also reduced the risk of progression by 30%, with hazard ratio 0.70 and p=0.008.

The commercial advantages management emphasizes are clinically meaningful survival evidence without biomarker selection, oral administration, an acceptable incremental safety burden and rapid inclusion as a preferred regimen in NCCN guidelines. The Q2 call added broad adoption across academic centers, community clinics and non-teaching hospitals.

The most important unanswered question is duration. Management said it was too early to assess real-world treatment duration because most patients had been followed for only weeks or a few months. It pointed to ROSELLA progression-free-survival data as the best current benchmark. That is reasonable, but real-world persistence, dose interruptions, payer mix and gross-to-net deductions will determine how much of the launch’s initial velocity becomes durable revenue.

Korlym and the authorized generic: still the core engine

Korlym remains approved for hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who failed surgery or are not candidates for surgery. Corcept’s authorized generic helps defend volume, but it carries a lower price and affects mix.

Q2 endocrine revenue of $208.6 million rose from $194.4 million a year earlier and by roughly 27% from Q1’s $164.9 million total, which at that point was entirely Korlym and authorized generic. The 10-Q says first-half revenue growth was driven by higher volume, partly offset by a 2.1% decline in average price due to higher authorized-generic volume.

Teva launched generic Korlym in January 2024. Corcept’s February 2026 appellate loss leaves the company exposed to further generic adoption; settlements could also allow Sun and Hikma to enter under specified conditions. Q2’s growth shows the branded/authorized-generic franchise can still expand, but price and tablet mix are what each quarterly report settles.

Management’s long-term goals and formal guidance are different things. Management said it expects the current Cushing’s business to reach at least $2 billion in annual revenue by the end of the decade and described more than $1 billion of potential annual U.S. Lifyorli revenue in the currently approved ovarian-cancer setting. These are strategic ambitions based on future adoption, not the company’s 2026 forecast and not guaranteed outcomes.

06 CATALYST and MOMENTUM are designed to expand the diagnosis funnel

Corcept’s endocrine thesis increasingly depends on the idea that hypercortisolism is materially underdiagnosed in populations usually treated as ordinary difficult-to-control diabetes or resistant hypertension. CATALYST found hypercortisolism in 24% of screened patients with difficult-to-control type 2 diabetes. Among patients with hypercortisolism randomized to Korlym or placebo, Corcept reported a 1.3 percentage-point HbA1c reduction with Korlym and improvements in weight, BMI and waist circumference.

The ADA 2026 update highlighted 71 patients already receiving a GLP-1 receptor agonist or tirzepatide. Corcept reported numerically greater improvements with Korlym versus placebo than in the overall treatment population. This is commercially interesting because it positions cortisol excess as a possible reason some patients remain uncontrolled despite advanced incretin therapy. It is still subgroup evidence, and a separate registration trial would be a different thing.

MOMENTUM screened more than 1,000 patients with resistant hypertension and found hypercortisolism in 27%. Management cited even higher prevalence when resistant hypertension and difficult-to-control diabetes overlapped: 32.6% in MOMENTUM and 36.6% in CATALYST. Publication and incorporation into clinical practice are the key transmission mechanisms between these prevalence studies and actual prescription growth.

24%

Hypercortisolism prevalence reported in difficult-to-control type 2 diabetes in CATALYST.

27%

Prevalence reported among screened patients with resistant hypertension in MOMENTUM.

December 17

FDA decision date that determines whether selective relacorilant can join the endocrine franchise.

07 What the Lifyorli label, ASCO data and treatment landscape mean in practice

ROSELLA was a multicenter, open-label study in 381 patients with recurrent platinum-resistant ovarian, fallopian-tube or primary-peritoneal cancer. Prior bevacizumab was required, patients could have received one to three prior systemic regimens, and the trial excluded patients who needed chronic or frequent glucocorticoids. That last point is clinically important because relacorilant antagonizes the glucocorticoid receptor and can interfere with corticosteroid treatment.

The label’s risk framework sits alongside the survival benefit, not behind it. Lifyorli is contraindicated in patients requiring systemic corticosteroids for lifesaving medical conditions. Warnings and precautions address neutropenia and serious infections, adrenal insufficiency, exacerbation of conditions treated with corticosteroids and embryo-fetal toxicity. Common adverse reactions and laboratory abnormalities include decreased hemoglobin and neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash and decreased appetite. Commercial adoption therefore depends not only on efficacy, but also on patient selection, supportive care, dose management and coordination when corticosteroids might otherwise be used.

ASCO 2026 answered a specific taxane-rechallenge question

The ASCO update did not change the approved label; it supplied subgroup context around ROSELLA. Corcept reported that the overall-survival benefit was observed across prespecified subgroups, including patients with recent taxane exposure. The company highlighted a hazard ratio of 0.67 in patients whose most recent regimen contained a taxane and 0.60 in patients with a taxane-free interval of six months or less.

This matters because platinum-resistant ovarian cancer is heterogeneous and physicians may hesitate to reuse a taxane-based regimen in patients recently exposed to a taxane. Consistency in those subgroups supports the clinical discussion, but subgroup estimates are less robust than the trial’s overall primary analysis and are not separate powered trials.

Competition is indication-specific, not one simple peer list

In Cushing’s syndrome, Corcept competes with surgery and radiation as well as therapies that reduce cortisol synthesis or action. The relevant treatment landscape includes products such as Signifor, Isturisa and Recorlev, plus ketoconazole and metyrapone in certain clinical contexts. Relacorilant’s proposed differentiation is selective glucocorticoid-receptor antagonism without progesterone-receptor binding and without some toxicities associated with existing therapies. That differentiation still requires the FDA to accept the submitted benefit-risk case.

In platinum-resistant ovarian cancer, the competitive set depends on biomarker status, prior therapy, treatment line, toxicity, access and guideline positioning. Lifyorli’s no-biomarker requirement broadens the eligible discussion, while the need to combine with nab-paclitaxel and manage corticosteroid-related considerations can limit convenience. The commercial question is not whether Lifyorli replaces every alternative; it is how often oncologists choose it within the defined label and how early in the platinum-resistant sequence they use it.

08 Multiple shots on goal, but the risk level is not equal

Why ALS remains optionality rather than a proven pillar

In DAZALS, 300 mg dazucorilant was associated in exploratory analyses with an 84% reduction in the risk of death at one year and an 87% reduction into year two. Those figures are attention-grabbing, but the randomized Phase 2 study did not meet its primary functional endpoint, ALSFRS-R. Non-serious gastrointestinal distress caused most discontinuations, which is why Corcept is running a dose-titration study before designing the planned pivotal trial.

The signal sits between two extremes, ignoring it and treating it as confirmatory Phase 3 evidence as if it were confirmatory Phase 3 evidence. A credible pivotal design, regulatory alignment, tolerability improvements and replication of survival benefit are all required.

09 Profitability recovered, but the permanent spending base is higher

For the first six months of 2026, revenue was $421.1 million versus $351.6 million a year earlier, but net income was only $11.2 million versus $55.7 million. This contrast matters: Q2 was strong, but the first half still contains the economic cost of the Q1 launch transition. At the operating line the half is negative — $429.4 million of expenses against $421.1 million of revenue leaves an operating loss of $8.3 million — so the $11.2 million of half-year net income comes from interest income and a tax benefit, not from operations. First-half operating cash flow was $16.8 million, down from $49.1 million in the comparable 2025 period.

Cash and investments rose from $515.4 million at March 31 to $544.6 million at June 30 and stood above $532.4 million at year-end 2025. This is not a financing-dependent biotech. Corcept can fund commercial expansion and multiple trials internally, although a broad program portfolio can still dilute returns if development spending lacks prioritization.

Financial strength: high gross margin, positive Q2 operating income, more than half a billion dollars in cash and investments, and no visible near-term need for an equity raise.

Financial watch: Q2 stock-based compensation was $29.9 million, SG&A remains far above the prior-year level, and first-half operating cash generation was modest relative to reported revenue.

10 Strong liquidity does not eliminate equity-compensation dilution

Corcept reported 107.9 million common shares on its June 30 equity statement and 108.1 million shares outstanding on July 22. The comparable year-end 2025 balance was approximately 106.0 million shares. The increase reflects incentive-plan issuances and equity compensation rather than a financing transaction.

For Q2 EPS, the basic weighted-average share count was 105.4 million and the diluted count was 118.4 million. That spread should not be read as 13 million shares that will necessarily issue immediately, but it shows that options, restricted awards and participating securities can meaningfully affect per-share economics when profitable. First-half stock-based compensation was $53.1 million when capitalized amounts are included.

Corcept’s board authorized a $200 million repurchase program in January 2024. As of June 30, 2026, $11.4 million remained available; the company made no open-market repurchases under the program in the first half of 2026. A strong balance sheet therefore provides flexibility, but the current authorization is nearly exhausted and the share count has continued to rise through compensation.

11 Founder-led science now faces a larger commercial execution test

Joseph K. Belanoff, M.D., co-founded Corcept and has led the company since its inception. The long tenure creates deep platform knowledge and strategic continuity. The Q2 call also showed a deliberately divisional commercial structure: Sean Maduck addressed endocrinology, Roberto Vieira addressed oncology, Atabak Mokari covered finance and Belanoff framed the pipeline and regulatory strategy.

The execution challenge is breadth. Management must defend Korlym economics, scale Lifyorli, support the Cushing’s review, prepare for a possible relacorilant launch, run multiple oncology trials, deliver MONARCH, design an ALS pivotal study and manage a materially higher SG&A base. Q2 demonstrates that the organization can generate leverage when revenue catches up with spending; one quarter does not yet prove sustained operating discipline.

What the register did between August 12 and August 26

Seven Form 4 filings cover transactions dated between August 12 and August 26, the last of them filed on August 28. One reports only gifted shares; the other six report sales, and together they come to 184,910 shares for about $22.1 million, at a weighted average of $119.55, into a price that ran up to a high of $126.06 on August 25.

Two of the six sales were not made under a Rule 10b5-1 plan. The aff10b5One box is unchecked on Robb’s August 17 filing and on Park’s August 26 filing, while the other four carry the box and name the adoption date of the plan in a footnote. That distinction is the whole point of the field: a plan adopted months earlier removes the timing decision from the insider, and a sale outside one does not. Together the two unplanned sales come to 36,685 shares and roughly $4.4 million.

Park’s filing takes her direct holding to zero. She net-exercised 30,000 options struck at $13.49, had 3,315 shares withheld by the company to cover the exercise price, and sold the remaining 26,685 at prices between $122.50 and $122.80. The Form 4 reports no shares beneficially owned directly following the transaction. A director exercising and selling in a single day is a common way to realize an award that is fully vested, and the filing describes the options as fully exercisable; it does not say anything about her view of the company.

Mahoney’s sale is the largest in dollar terms at about $12.25 million across four price bands from $117.47 to $119.64, and it leaves 1,133,539 shares. Wilson’s 10,000 shares leave 1,074,543, held through the James N. Wilson and Pamela D. Wilson Trust, over which he reports voting power while disclaiming beneficial ownership beyond his pecuniary interest. Maduck ends the period with 9,755 shares directly, after exercises at $8.27 on August 14 and $11.35 on August 25 against sales above $114. Robb is left with 39,716 shares, a figure that includes unvested restricted stock awards and shares held through a revocable trust and two custodial accounts for his children.

What none of this settles. Insider sales are a fact about individual portfolios, not a forecast: a plan adopted in December 2025 was written before the second-quarter results and before the run in the share price, and the two unplanned sales are still consistent with tax, diversification or personal reasons the filings do not disclose. What is verifiable is the sequence: the selling clustered in the two weeks the stock spent above $110, and the shares closed at $113.88 on August 28, 9.7% below the August 25 high and still above where they traded before the July results.

Renaissance Technologies dropped below the 5% line

A Schedule 13G/A filed on August 13 by Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reports 5,261,628 shares, or 4.90% of the class, as of April 1, 2026. The 2026 proxy had the same manager at 5,758,528 shares, or 5.4%. Falling below five per cent ends the Schedule 13G obligation, so the amendment is the last figure that filing series will carry unless the position crosses back over the line. The manager keeps reporting the position quarterly on Form 13F, which is a different record with a different lag. The event date is April 1: it describes the position five months ago, not today.

Institutional ownership provides stability, not immunity from volatility

Corcept’s 2026 proxy used 107,356,686 shares outstanding as of April 9 for ownership calculations. It identified BlackRock with 11,539,099 shares, or 10.7%; Vanguard with 9,537,532 shares, or 8.9%; Ingalls & Snyder-related entities with 8,173,721 shares, or 7.6%; and Renaissance Technologies with 5,758,528 shares, or 5.4%. These positions show that CORT is institutionally owned rather than a thinly held micro-cap.

Institutional concentration can improve liquidity and research coverage, but it can also magnify repricing when models change together around a launch, FDA event or earnings surprise. Ownership percentages are historical snapshots that change through trading and quarterly reporting; they are not live positions at any date after the proxy record.

Credibility checkpoint: management described relacorilant availability as expected shortly after the December 17 PDUFA date. That is a forward-looking assumption dependent on FDA approval, final labeling, manufacturing readiness and launch execution, not a confirmed commercial date.

12 The earnings-call questions focused on sustainability, not the headline beat

The Q&A was short and management provided limited quantitative detail beyond starts, prescribers and rough channel mechanics. The clean read is positive, but the company did not disclose average realized revenue per Lifyorli patient, active patients at quarter-end, discontinuation rates, average treatment duration or separate full-year revenue guidance by product.

13 What matters next for $CORT

For cross-company tracking, readers can also use the Merlintrader Biotech Catalyst Calendar.

14 The two honest versions of the CORT thesis

Bull case

Lifyorli’s first-quarter revenue proves that the product can scale rapidly; repeat prescribing and duration sustain growth through 2027. Korlym and the authorized generic continue to add patients despite lower-price mix, while screening driven by CATALYST and MOMENTUM expands the diagnosis pool.

The FDA approves relacorilant for Cushing’s on or before December 17, giving Corcept a selective successor/expansion asset. BELLA Part A supports oncology expansion, MONARCH justifies Phase 3, and cash generation funds the pipeline without external capital.

Bear case

Initial Lifyorli demand contains more one-time early adopters than recurring breadth; treatment duration or gross-to-net economics disappoint. Generic Korlym mix weighs on average price, and the commercial expense base remains high enough to compress profits if revenue growth normalizes.

The FDA remains unconvinced by the additional Cushing’s analyses, or final labeling limits the opportunity. BELLA or MONARCH data are mixed, and the ALS program cannot overcome the failed functional endpoint and tolerability problem. After the post-Q2 re-rating, the stock has less tolerance for ordinary execution misses.

Falsifiers and monitoring rules

Evidence that strengthens the thesis: sequential Lifyorli growth with repeat prescribers and stable payer access; continued endocrine patient additions; operating leverage; FDA approval; and clean, decision-useful BELLA/MONARCH data.

Evidence that weakens the thesis: falling Lifyorli starts, short real-world duration, worsening gross-to-net, accelerating generic price erosion, another FDA setback, higher cash burn or pipeline data that fail to justify Phase 3 investment.

15 Key risks that outlast the rally

Regulatory risk

The December Cushing’s decision follows a serious CRL. Acceptance of a resubmission confirms review, not approvability. The FDA may reject, delay, narrow the label or impose additional requirements.

Commercial-duration risk

Q2 proves rapid initiation, not long-term persistence. Ovarian-cancer treatment duration, tolerability, reimbursement and physician repetition determine the recurring revenue curve.

Generic and pricing risk

Teva is already in the market; Sun and Hikma may enter under settlements. Authorized-generic volume protects access but lowers average price and can reduce revenue quality.

Cost-base risk

SG&A increased 51% year over year. If growth slows while commercial investment remains elevated, Q2’s operating leverage can reverse.

Pipeline interpretation risk

ALS survival findings are exploratory after a failed primary endpoint. ADA subgroup evidence, early immunotherapy work and management’s fivefold oncology expansion language require confirmation.

Valuation and expectation risk

The 27.29% post-earnings move reflects a much higher expectation set. Strong fundamentals can coexist with sharp downside if future results merely meet rather than exceed a re-rated bar.

16 Three sessions gave back part of the re-rating

Before Q2, the dominant debates were whether Lifyorli could overcome launch friction, whether Korlym weakness was temporary and whether Corcept’s Q1 loss signaled an uncontrolled spending cycle. The print answered all three questions favorably for one quarter. That explains the unusually strong first-session reaction.

What happened next is the part the July narrative does not cover. The stock reached $126.06 on August 25 and closed at $113.88 on August 28, 9.7% lower in three sessions and 3.75% below the $118.32 post-earnings close. That gives back part of the move, not all of it: the +27.29% session of July 30 implies a pre-release close near $92.95, so at $113.88 the stock is still about 22% above where it traded before the results, and roughly a sixth of the re-rating has come off. Over the same stretch the Stocktwits normalised score fell from 84 on July 31 to 39, and five insiders filed six sales totalling 184,910 shares between August 14 and August 26. None of those three facts explains the others, and no company disclosure was issued in the window. Retail discussion on X, Stocktwits and message boards can amplify volatility but is not evidence. The more durable indicators are product-level revenue, patient initiation, repeat prescribing, specialty-pharmacy execution, average price, operating cash flow and formal regulatory documents.

No individual analyst target changes are listed here because no complete set of same-day actions could be verified on primary or major-wire sources. The aggregate figure in the snapshot is a third-party average from Finviz, read on August 28, 2026. Pre-print consensus figures vary by provider and methodology; the article therefore uses the company’s reported results and official guidance as the factual base.

The panel that follows is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

17 Primary documents and verification links

• Form 4 for Gary Charles Robb, filed August 18, 2026: 10,000 shares sold on August 17 at a weighted average of $116.2572 within a $116.00 to $116.54 range, with the Rule 10b5-1 box unchecked.
• Form 4 for Kimberly Park, filed August 28, 2026: 30,000 options net-exercised at $13.49 on August 26, 3,315 shares withheld to cover the exercise price and 26,685 sold at a weighted average of $122.5471, leaving no shares owned directly. Rule 10b5-1 box unchecked.
• Form 4 for David L. Mahoney, filed August 20, 2026: 103,606 shares sold on August 18 across four price bands from $117.4716 to $119.6381, under a plan adopted May 11, 2026.
• Form 4 for James N. Wilson, filed August 18, 2026: 10,000 shares sold on August 14 from $110.4949 to $112.6398, under a plan adopted March 12, 2026.
• Form 4 for Sean Maduck, filed August 27, 2026: 30,955 options exercised at $11.35 on August 25 and the same number sold from $125.4676 to $126.0588, under a plan adopted December 8, 2025.
• Schedule 13G/A filed by Renaissance Technologies, August 13, 2026: 5,261,628 shares, 4.90% of the class, as of April 1, 2026.
• Corcept Q2 2026 financial results and corporate update — July 29, 2026
• SEC EDGAR filings for Corcept Therapeutics, including the Q2 2026 Form 10-Q
• Official Q2 2026 earnings-call event and webcast page
• FDA approval notice for relacorilant plus nab-paclitaxel
• Corcept Lifyorli approval release
• Corcept Cushing’s relacorilant NDA resubmission — June 17, 2026
• Corcept relacorilant Cushing’s Complete Response Letter update
• Corcept update on Teva / Korlym patent litigation
• Corcept Q1 2026 financial results
• Corcept Q4 and full-year 2025 financial results
• Corcept 2026 definitive proxy statement — ownership and governance
• Corcept ASCO 2026 ROSELLA subgroup update
• Corcept ADA 2026 CATALYST and MOMENTUM update

Market price reference: CORT’s July 30, 2026 regular-session close of $118.32 and +27.29% session move, read on August 28, 2026. Prices change continuously. Clinical timelines described as “expected” or “planned” are company guidance and may change.